Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2019

07.06.2018 | Original Article

FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging

verfasst von: A. P. Douglas, K. A. Thursky, L. J. Worth, E. Drummond, A. Hogg, R. J. Hicks, M. A. Slavin

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Invasive fungal infections (IFIs) are common in immunocompromised patients. While early diagnosis can reduce otherwise high morbidity and mortality, conventional CT has suboptimal sensitivity and specificity. Small studies have suggested that the use of FDG PET/CT may improve the ability to detect IFI. The objective of this study was to describe the proven and probable IFIs detected on FDG PET/CT at our centre and compare the performance with that of CT for localization of infection, dissemination and response to therapy.

Methods

FDG PET/CT reports for adults investigated at Peter MacCallum Cancer Centre were searched using keywords suggestive of fungal infection. Chart review was performed to describe the risk factors, type and location of IFIs, indication for FDG PET/CT, and comparison with CT for the detection of infection, and its dissemination and response to treatment.

Results

Between 2007 and 2017, 45 patients had 48 proven/probable IFIs diagnosed prior to or following FDG PET/CT. Overall 96% had a known malignancy with 78% being haematological. FDG PET/CT located clinically occult infection or dissemination to another organ in 40% and 38% of IFI patients, respectively. Of 40 patients who had both FDG PET/CT and CT, sites of IFI dissemination were detected in 35% and 5%, respectively (p < 0.001). Of 18 patents who had both FDG PET/CT and CT follow-up imaging, there were discordant findings between the two imaging modalities in 11 (61%), in whom normalization of FDG avidity of a lesion suggested resolution of active infection despite a residual lesion on CT.

Conclusion

FDG PET/CT was able to localize clinically occult infection and dissemination and was particularly helpful in demonstrating response to antifungal therapy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tang JL, Kung HC, Lei WC, Yao M, Wu UI, Hsu SC, et al. High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan. PLoS One. 2015;10(6):e0128410.CrossRef Tang JL, Kung HC, Lei WC, Yao M, Wu UI, Hsu SC, et al. High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan. PLoS One. 2015;10(6):e0128410.CrossRef
2.
Zurück zum Zitat Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–75.PubMed Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–75.PubMed
3.
Zurück zum Zitat Shi JM, Pei XY, Luo Y, Tan YM, Tie RX, He JS, et al. Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years. J Zhejiang Univ Sci B. 2015;16(9):796–804.CrossRef Shi JM, Pei XY, Luo Y, Tan YM, Tie RX, He JS, et al. Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years. J Zhejiang Univ Sci B. 2015;16(9):796–804.CrossRef
4.
Zurück zum Zitat Biehl LM, Vehreschild JJ, Liss B, Franke B, Markiefka B, Persigehl T, et al. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. J Antimicrob Chemother. 2016;71(9):2634–41.CrossRef Biehl LM, Vehreschild JJ, Liss B, Franke B, Markiefka B, Persigehl T, et al. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. J Antimicrob Chemother. 2016;71(9):2634–41.CrossRef
5.
Zurück zum Zitat Teng JC, Slavin MA, Teh BW, Lingaratnam SM, Ananda-Rajah MR, Worth LJ, et al. Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica. 2015;100(11):e462–6.CrossRef Teng JC, Slavin MA, Teh BW, Lingaratnam SM, Ananda-Rajah MR, Worth LJ, et al. Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica. 2015;100(11):e462–6.CrossRef
6.
Zurück zum Zitat Teh BW, Teng JC, Urbancic K, Grigg A, Harrison SJ, Worth LJ, et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 2015;100(1):e28–31.CrossRef Teh BW, Teng JC, Urbancic K, Grigg A, Harrison SJ, Worth LJ, et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 2015;100(1):e28–31.CrossRef
7.
Zurück zum Zitat Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.CrossRef Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.CrossRef
8.
Zurück zum Zitat Horn DL, Freifeld AG, Schuster MG, Azie NE, Franks B, Kauffman CA. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance® registry. Mycoses. 2014;57(11):652–8.CrossRef Horn DL, Freifeld AG, Schuster MG, Azie NE, Franks B, Kauffman CA. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance® registry. Mycoses. 2014;57(11):652–8.CrossRef
9.
Zurück zum Zitat Nucci M, Marr KA, Vehreschild MJGT, de Souza CA, Velasco E, Cappellano P, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20(6):580–5.CrossRef Nucci M, Marr KA, Vehreschild MJGT, de Souza CA, Velasco E, Cappellano P, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20(6):580–5.CrossRef
10.
Zurück zum Zitat Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–66.CrossRef Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–66.CrossRef
11.
Zurück zum Zitat Rolfe NE, Sandin RL, Greene JN. Scedosporium infections at a Cancer Centre over a 10-year period (2001-2010). Infect Dis Clin Pract. 2014;22(2):71–4.CrossRef Rolfe NE, Sandin RL, Greene JN. Scedosporium infections at a Cancer Centre over a 10-year period (2001-2010). Infect Dis Clin Pract. 2014;22(2):71–4.CrossRef
12.
Zurück zum Zitat Farmakiotis D, Kyvernitakis A, Tarrand JJ, Kontoyiannis DP. Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation. Clin Microbiol Infect. 2015;21(1):79–86.CrossRef Farmakiotis D, Kyvernitakis A, Tarrand JJ, Kontoyiannis DP. Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation. Clin Microbiol Infect. 2015;21(1):79–86.CrossRef
13.
Zurück zum Zitat Gafter-Gvili A, Paul M, Bernstine H, Vidal L, Ram R, Raanani P, et al. The role of 18F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia. Leuk Res. 2013;37(9):1057–62.CrossRef Gafter-Gvili A, Paul M, Bernstine H, Vidal L, Ram R, Raanani P, et al. The role of 18F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia. Leuk Res. 2013;37(9):1057–62.CrossRef
14.
Zurück zum Zitat Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis. 2013;13(6):519–28.CrossRef Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis. 2013;13(6):519–28.CrossRef
15.
Zurück zum Zitat Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007;139(4):519–31.CrossRef Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007;139(4):519–31.CrossRef
16.
Zurück zum Zitat Douglas A, Lau E, Thursky K, Slavin M. What, where and why: exploring fluorodeoxyglucose-PET’s ability to localise and differentiate infection from cancer. Curr Opin Infect Dis. 2017;30(6):552–64.CrossRef Douglas A, Lau E, Thursky K, Slavin M. What, where and why: exploring fluorodeoxyglucose-PET’s ability to localise and differentiate infection from cancer. Curr Opin Infect Dis. 2017;30(6):552–64.CrossRef
17.
Zurück zum Zitat Hot A, Maunoury C, Poiree S, Lanternier F, Viard JP, Loulergue P, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17(3):409–17.CrossRef Hot A, Maunoury C, Poiree S, Lanternier F, Viard JP, Loulergue P, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17(3):409–17.CrossRef
18.
Zurück zum Zitat Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol. 2008;46(1):23–9.CrossRef Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol. 2008;46(1):23–9.CrossRef
19.
Zurück zum Zitat Vos FJ, Donnelly JP, Oyen WJG, Kullberg BJ, Bleeker-Rovers CP, Blijlevens NMA. 18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39(1):120–8.CrossRef Vos FJ, Donnelly JP, Oyen WJG, Kullberg BJ, Bleeker-Rovers CP, Blijlevens NMA. 18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39(1):120–8.CrossRef
20.
Zurück zum Zitat Guy SD, Tramontana AR, Worth LJ, Lau E, Hicks RJ, Seymour JF, et al. Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. Eur J Nucl Med Mol Imaging. 2012;39(8):1348–55.CrossRef Guy SD, Tramontana AR, Worth LJ, Lau E, Hicks RJ, Seymour JF, et al. Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. Eur J Nucl Med Mol Imaging. 2012;39(8):1348–55.CrossRef
21.
Zurück zum Zitat Koh KC, Slavin MA, Thursky KA, Lau E, Hicks RJ, Drummond E, et al. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. Leuk Lymphoma. 2012;53(10):1889–95.CrossRef Koh KC, Slavin MA, Thursky KA, Lau E, Hicks RJ, Drummond E, et al. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. Leuk Lymphoma. 2012;53(10):1889–95.CrossRef
22.
Zurück zum Zitat Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol. 2005;23(31):7857–63.CrossRef Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol. 2005;23(31):7857–63.CrossRef
23.
Zurück zum Zitat Hofman MS, Hicks RJ. How we read oncologic FDG PET/CT. Cancer Imaging. 2016;16(1):35.CrossRef Hofman MS, Hicks RJ. How we read oncologic FDG PET/CT. Cancer Imaging. 2016;16(1):35.CrossRef
24.
Zurück zum Zitat Miyazaki Y, Nawa Y, Nakase K, Kohashi S, Kadohisa S, Hiraoka A, et al. FDG-PET can evaluate the treatment for fungal liver abscess much earlier than other imagings. Ann Hematol. 2011;90(12):1489–90.CrossRef Miyazaki Y, Nawa Y, Nakase K, Kohashi S, Kadohisa S, Hiraoka A, et al. FDG-PET can evaluate the treatment for fungal liver abscess much earlier than other imagings. Ann Hematol. 2011;90(12):1489–90.CrossRef
25.
Zurück zum Zitat Xu B, Shi P, Wu H, Guo X, Wang Q, Zhou S. Utility of FDG PET/CT in guiding antifungal therapy in acute leukemia patients with chronic disseminated candidiasis. Clin Nucl Med. 2010;35(8):567–70.CrossRef Xu B, Shi P, Wu H, Guo X, Wang Q, Zhou S. Utility of FDG PET/CT in guiding antifungal therapy in acute leukemia patients with chronic disseminated candidiasis. Clin Nucl Med. 2010;35(8):567–70.CrossRef
26.
Zurück zum Zitat Wang C, Jia N, Zhang L, Liu K, Liu H, Yu H. Imaging findings of cryptococcal infection of the thoracic spine. Int J Infect Dis. 2014;29:162–5.CrossRef Wang C, Jia N, Zhang L, Liu K, Liu H, Yu H. Imaging findings of cryptococcal infection of the thoracic spine. Int J Infect Dis. 2014;29:162–5.CrossRef
27.
Zurück zum Zitat Altini C, Niccoli Asabella A, Ferrari C, Rubini D, Dicuonzo F, Rubini G. (18)F-FDG PET/CT contribution to diagnosis and treatment response of rhino-orbital-cerebral mucormycosis. Hell J Nucl Med. 2015;18(1):68–70.PubMed Altini C, Niccoli Asabella A, Ferrari C, Rubini D, Dicuonzo F, Rubini G. (18)F-FDG PET/CT contribution to diagnosis and treatment response of rhino-orbital-cerebral mucormycosis. Hell J Nucl Med. 2015;18(1):68–70.PubMed
28.
Zurück zum Zitat Muller N, Kessler R, Caillard S, Epailly E, Hubele F, Heimburger C, et al. 18F-FDG PET/CT for the diagnosis of malignant and infectious complications after solid organ transplantation. Nucl Med Mol Imaging. 2017;51(1):58–68.CrossRef Muller N, Kessler R, Caillard S, Epailly E, Hubele F, Heimburger C, et al. 18F-FDG PET/CT for the diagnosis of malignant and infectious complications after solid organ transplantation. Nucl Med Mol Imaging. 2017;51(1):58–68.CrossRef
29.
Zurück zum Zitat Karunanithi S, Kumar G, Sharma SK, Jain D, Gupta A, Kumar R. Staging and response of sternal histoplasmosis by 18F-FDG PET/CT. Clin Nucl Med. 2015;40(3):231–3.CrossRef Karunanithi S, Kumar G, Sharma SK, Jain D, Gupta A, Kumar R. Staging and response of sternal histoplasmosis by 18F-FDG PET/CT. Clin Nucl Med. 2015;40(3):231–3.CrossRef
30.
Zurück zum Zitat De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.CrossRef De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.CrossRef
31.
Zurück zum Zitat Avet J Jr, Granjon D, Prevot-Bitot N, Isnardi V, Berger C, Stephan JL, et al. Monitoring of systemic candidiasis by 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36(11):1900.CrossRef Avet J Jr, Granjon D, Prevot-Bitot N, Isnardi V, Berger C, Stephan JL, et al. Monitoring of systemic candidiasis by 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36(11):1900.CrossRef
32.
Zurück zum Zitat Bleeker-Rovers CP, Warris A, Drenth JPH, Corstens FHM, Oyen WJG, Kullberg BJ. Diagnosis of Candida lung abscesses by 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Infect. 2005;11(6):493–5.CrossRef Bleeker-Rovers CP, Warris A, Drenth JPH, Corstens FHM, Oyen WJG, Kullberg BJ. Diagnosis of Candida lung abscesses by 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Infect. 2005;11(6):493–5.CrossRef
33.
Zurück zum Zitat Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg. 2006;82(3):1016–20.CrossRef Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg. 2006;82(3):1016–20.CrossRef
Metadaten
Titel
FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging
verfasst von
A. P. Douglas
K. A. Thursky
L. J. Worth
E. Drummond
A. Hogg
R. J. Hicks
M. A. Slavin
Publikationsdatum
07.06.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-018-4062-8

Weitere Artikel der Ausgabe 1/2019

European Journal of Nuclear Medicine and Molecular Imaging 1/2019 Zur Ausgabe